AVITA Medical Q3 commercial rev $9.0M, up 30%; raises FY guidance; pivotal trial endpoints met

AVITA Medical, Inc.

2022-Q3 EPS reported $0.85 revenue$24,966,000

Commercial revenue (ex-BARDA) $9.0M, +30% YoY; total revenue $9.1M.
Net loss $5.6M ($0.22/sh); cash $88.2M, no debt.
Soft-tissue repair trial met co-primary endpoints; vitiligo trial achieved super-superiority.
FY 2022 commercial revenue guidance raised to $33-34M from $30M.
Japan MHLW grants RECELL approval; partner COSMOTEC launching in Q4 2022.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AVITA Medical, Inc. reported full year 2022 results: revenue $33.0-34.0 million. Guidance raised.

Period: full year 2022
Revenue: $33.0-34.0 million
Guidance: raised
Result: guidance update

Exact text from the filing

full year 2022 commercial revenue (excluding BARDA revenues) is expected to be $33.0-34.0 million, an increase from our prior guidance of $30 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AVITA Medical, Inc. reported third quarter ended September 30, 2022 results: revenue $9.0 million, net income $5.6 million, EPS $0.22 per share.

Period: third quarter ended September 30, 2022
Revenue: $9.0 million
Net income: $5.6 million
EPS: $0.22 per share
Result: reported results

Exact text from the filing

Reported commercial revenue, which excludes BARDA revenue, of $9.0 million, a 30% increase compared to $6.9 million in the corresponding period in the prior year

View on SEC.gov

12 earnings releases filed in the last 30 days. Browse all earnings releases →

AVITA Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-283537

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.